CR20180231A - Composiciones y métodos para ionhibir la expresión génica del lpa - Google Patents
Composiciones y métodos para ionhibir la expresión génica del lpaInfo
- Publication number
- CR20180231A CR20180231A CR20180231A CR20180231A CR20180231A CR 20180231 A CR20180231 A CR 20180231A CR 20180231 A CR20180231 A CR 20180231A CR 20180231 A CR20180231 A CR 20180231A CR 20180231 A CR20180231 A CR 20180231A
- Authority
- CR
- Costa Rica
- Prior art keywords
- lpa
- gene expression
- agents
- compositions
- ionhibit
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 230000009368 gene silencing by RNA Effects 0.000 abstract 5
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 102100040214 Apolipoprotein(a) Human genes 0.000 abstract 3
- 101150091521 lpa gene Proteins 0.000 abstract 2
- 101710115418 Apolipoprotein(a) Proteins 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 210000005229 liver cell Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562235816P | 2015-10-01 | 2015-10-01 | |
| US201662346304P | 2016-06-06 | 2016-06-06 | |
| US201662383221P | 2016-09-02 | 2016-09-02 | |
| PCT/US2016/054729 WO2017059223A2 (en) | 2015-10-01 | 2016-09-30 | Compositions and methods for inhibiting gene expression of lpa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20180231A true CR20180231A (es) | 2018-05-31 |
Family
ID=58424351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20180231A CR20180231A (es) | 2015-10-01 | 2016-09-30 | Composiciones y métodos para ionhibir la expresión génica del lpa |
Country Status (37)
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7718133B2 (en) | 2003-10-09 | 2010-05-18 | 3M Innovative Properties Company | Multilayer processing devices and methods |
| CN109069529B (zh) * | 2016-03-07 | 2021-08-20 | 箭头药业股份有限公司 | 用于治疗性化合物的靶向配体 |
| CN109462981B (zh) | 2016-09-02 | 2023-07-07 | 箭头药业股份有限公司 | 靶向配体 |
| LT3607069T (lt) * | 2017-04-05 | 2023-01-10 | Silence Therapeutics Gmbh | Produktai ir kompozicijos |
| CR20190572A (es) * | 2017-07-06 | 2020-05-23 | Arrowhead Pharmaceuticals Inc | AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO |
| SG11201912178VA (en) * | 2017-09-11 | 2020-01-30 | Arrowhead Pharmaceuticals Inc | Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3) |
| KR102737464B1 (ko) * | 2017-09-14 | 2024-12-02 | 애로우헤드 파마슈티컬스 인코포레이티드 | 안지오포이에틴-유사 3 (ANGPTL3)의 발현을 억제하기 위한 RNAi 작용제 및 조성물, 및 사용 방법 |
| SG11202003126VA (en) | 2017-10-04 | 2020-05-28 | Avidity Biosciences Inc | Nucleic acid-polypeptide compositions and uses thereof |
| CN111212909A (zh) * | 2017-10-17 | 2020-05-29 | 箭头药业股份有限公司 | 用于抑制去唾液酸糖蛋白受体1的表达的RNAi试剂和组合物 |
| EP3483270A1 (en) * | 2017-11-13 | 2019-05-15 | Silence Therapeutics GmbH | Products and compositions |
| HUE061265T2 (hu) | 2017-11-13 | 2023-06-28 | Silence Therapeutics Gmbh | Nukleinsavak LPA expressziójának gátlására sejtben |
| SG11202101698WA (en) * | 2018-09-19 | 2021-04-29 | Arrowhead Pharmaceuticals Inc | Rnai agents for inhibiting expression of 17beta-hsd type 13- (hsd17b13), compositions thereof, and methods of use |
| ES2932295T3 (es) * | 2018-11-13 | 2023-01-17 | Silence Therapeutics Gmbh | Acidos nucleicos para inhibir la expresión de LPA en una célula |
| JP7592034B2 (ja) * | 2019-06-06 | 2024-11-29 | アビディティー バイオサイエンシーズ，インク． | 核酸ポリペプチド組成物およびその使用 |
| US20220307024A1 (en) * | 2019-06-17 | 2022-09-29 | Alnylam Pharmaceuticals, Inc. | Delivery of oligonucleotides to the striatum |
| CN112442499A (zh) * | 2019-08-30 | 2021-03-05 | 恩智（广州）医药科技有限公司 | 一种抑制MCM7的siRNA、组合物及其应用 |
| AU2020399636A1 (en) | 2019-12-09 | 2022-06-02 | Amgen Inc. | RNAi constructs and methods for inhibiting LPA expression |
| WO2021194999A1 (en) * | 2020-03-23 | 2021-09-30 | Amgen Inc. | Monoclonal antibodies to chemically-modified nucleic acids and uses thereof |
| IL300338A (en) * | 2020-08-05 | 2023-04-01 | Dicerna Pharmaceuticals Inc | Compounds and methods for inhibiting the expression of LPA |
| JP2023545502A (ja) * | 2020-10-16 | 2023-10-30 | サノフイ | リポタンパク質（ａ）を阻害するためのｒｎａ組成物および方法 |
| MX2023005198A (es) | 2020-11-05 | 2023-05-16 | Amgen Inc | Metodos para tratar la enfermedad cardiovascular aterosclerotica con constructos de iarn dirigidos a lpa. |
| WO2022121959A1 (zh) * | 2020-12-09 | 2022-06-16 | 纳肽得有限公司 | siRNA分子及其在治疗冠状动脉疾病中的应用 |
| WO2022136466A1 (en) | 2020-12-23 | 2022-06-30 | Argonaute RNA Limited | Treatment of cardiovascular disease |
| WO2022266316A1 (en) | 2021-06-18 | 2022-12-22 | Hongene Biotech Corporation | Functionalized n-acetylgalactosamine nucleosides |
| JP2024532271A (ja) | 2021-08-30 | 2024-09-05 | ホンジーン バイオテック コーポレイション | 官能化ｎ－アセチルガラクトサミンアナログ |
| JP2024531728A (ja) | 2021-09-14 | 2024-08-29 | アルゴノート アールエヌエー リミテッド | 心血管疾患の処置 |
| EP4403633A1 (en) * | 2021-09-18 | 2024-07-24 | Genoval Therapeutics Co., Ltd. | Lpa inhibitor and use thereof |
| WO2023114746A1 (en) | 2021-12-15 | 2023-06-22 | Hongene Biotech Corporation | Functionalized n-acetylgalactosamine analogs |
| EP4450624A4 (en) * | 2021-12-16 | 2025-03-26 | Tuojie Biotech (Shanghai) Co., Ltd. | LPA-TARGETTING SIRNA AND CONJUGATE |
| CN114703184B (zh) * | 2022-03-11 | 2024-06-18 | 厦门甘宝利生物医药有限公司 | Lpa抑制剂及其用途 |
| CN119698469A (zh) * | 2022-08-11 | 2025-03-25 | 益杰立科(上海)生物科技有限公司 | 一种表观编辑靶点的方法及用途 |
| CN115851723B (zh) * | 2022-10-24 | 2023-10-03 | 厦门甘宝利生物医药有限公司 | 一种抑制lpa基因表达的rna抑制剂及其应用 |
| US12116382B2 (en) | 2022-11-28 | 2024-10-15 | Hongene Biotech Corporation | Functionalized N-acetylgalactosamine analogs |
| AU2024207615A1 (en) * | 2023-01-13 | 2025-07-24 | Eli Lilly And Company | Therapeutic oligonucleotide-containing pharmaceutical compositions and dosing regimens using the same |
| CN118773191A (zh) * | 2023-04-03 | 2024-10-15 | 翰森（上海）健康科技有限公司 | 靶向LPA基因的RNAi剂及其用途 |
| CN121127587A (zh) * | 2023-04-24 | 2025-12-12 | 上海京新生物医药有限公司 | 用于抑制LPA表达的RNAi剂及其应用 |
| CN119343449A (zh) * | 2023-05-24 | 2025-01-21 | 云合智药（苏州）生物科技有限公司 | 用于抑制angptl3表达的rnai剂及其应用 |
| WO2024249680A2 (en) * | 2023-05-31 | 2024-12-05 | Arrowhead Pharmaceuticals, Inc. | Hepatic Delivery Platforms For Multimeric RNAi Agent Conjugates and Methods of Use Thereof |
| CN121079106A (zh) * | 2023-05-31 | 2025-12-05 | 上海拓界生物医药科技有限公司 | 一种靶向LPA的dsRNA及其应用 |
| DE102023115075A1 (de) * | 2023-06-07 | 2024-12-12 | B.Braun Avitum Ag | Schlauchrollenpumpe |
| WO2025064821A2 (en) | 2023-09-21 | 2025-03-27 | Ionis Pharmaceuticals, Inc. | Compounds and methods for inhibiting lpa |
| WO2025082058A1 (zh) * | 2023-10-16 | 2025-04-24 | 润佳(上海)医药技术有限公司 | 一种抑制LPA基因表达的dsRNA及其用途 |
| WO2025087442A1 (zh) * | 2023-10-27 | 2025-05-01 | 北京安龙生物医药有限公司 | 靶向脂蛋白a的寡核苷酸及其用途 |
| WO2025103391A1 (zh) * | 2023-11-15 | 2025-05-22 | 北京加科瑞康医药科技有限公司 | 用于抑制lpa的基因表达的sirna，含其的组合物及其用途 |
| CN120020252A (zh) * | 2023-11-17 | 2025-05-20 | 纳肽得(青岛)生物医药有限公司 | 抑制LPA表达的siRNA及其用途 |
| CN120098993A (zh) * | 2023-12-05 | 2025-06-06 | 广东东阳光药业股份有限公司 | 一种新型的双链siRNA、其缀合物及其用途 |
| CN120485189B (zh) * | 2025-07-16 | 2025-10-17 | 北京悦康科创医药科技股份有限公司 | 靶向调控LPA基因表达的siRNA及其用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
| US5599706A (en) | 1994-09-23 | 1997-02-04 | Stinchcomb; Dan T. | Ribozymes targeted to apo(a) mRNA |
| EP1159441B8 (en) | 1999-03-10 | 2008-10-29 | Marie Curie Cancer Care | Delivery of nucleic acids and proteins to cells |
| RU2322500C2 (ru) * | 2000-12-01 | 2008-04-20 | Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. | Малые молекулы рнк, опосредующие интерференцию рнк |
| US7227014B2 (en) | 2001-08-07 | 2007-06-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (a) expression |
| US7259150B2 (en) | 2001-08-07 | 2007-08-21 | Isis Pharmaceuticals, Inc. | Modulation of apolipoprotein (a) expression |
| WO2004081198A2 (en) | 2003-03-12 | 2004-09-23 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods for modulating angiogenesis with apelin compositions |
| JP5243789B2 (ja) | 2004-03-15 | 2013-07-24 | シティ・オブ・ホープ | 二本鎖ｒｎａによる遺伝子発現の特異的阻害のための方法及び組成物 |
| BRPI0715375A2 (pt) * | 2006-08-18 | 2013-06-18 | Hoffmann La Roche | policonjugados para distribuiÇço in vivo de polinucleotÍdeos |
| CN105907756A (zh) | 2008-12-18 | 2016-08-31 | 戴瑟纳制药公司 | 延长的dicer酶底物和特异性抑制基因表达的方法 |
| WO2010093788A2 (en) | 2009-02-11 | 2010-08-19 | Dicerna Pharmaceuticals, Inc. | Multiplex dicer substrate rna interference molecules having joining sequences |
| ES2562817T3 (es) | 2010-02-24 | 2016-03-08 | Arrowhead Research Corporation | Composiciones para el suministro dirigido de ARNip |
| US8865675B2 (en) * | 2010-05-12 | 2014-10-21 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein B |
| KR20130132475A (ko) * | 2010-12-17 | 2013-12-04 | 애로우헤드 리서치 코오포레이션 | ｓｉＲＮＡ의 갈락토오스 클러스터-약동학적 조절제 표적 물질 |
| US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
| MX347298B (es) | 2010-12-29 | 2017-04-21 | Arrowhead Res Corp | Conjugados de suministro de polinucleotidos in vivo que tienen acoplamientos sensibles a enzima. |
| MX2014001971A (es) | 2011-08-26 | 2014-03-31 | Arrowhead Res Corp | Polimeros de poli(vinilester) para suministro de acido nucleico in vivo. |
| MY167390A (en) * | 2011-11-18 | 2018-08-16 | Alnylam Pharmaceuticals Inc | Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases |
| MX2014001965A (es) | 2012-04-18 | 2014-03-31 | Arrowhead Res Corp | Polimeros de poli(acrilato) para suministro de acido nucleico in vivo. |
| HRP20201426T1 (hr) | 2012-05-24 | 2020-11-27 | Ionis Pharmaceuticals, Inc. | Postupci i pripravci za moduliranje ekspresije apolipoproteina (a) |
| US9999680B2 (en) * | 2013-02-28 | 2018-06-19 | Immunogen, Inc. | Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents |
| KR102482890B1 (ko) | 2013-05-01 | 2022-12-30 | 아이오니스 파마수티컬즈, 인코포레이티드 | 아포지질단백질 (a) 발현을 조절하는 조성물 및 방법 |
| US20160272970A1 (en) | 2015-03-17 | 2016-09-22 | Arrowhead Madison Inc. | RNA Interference Agents |
| MX2017014641A (es) | 2015-05-29 | 2018-01-23 | Arrowhead Pharmaceuticals Inc | Composiciones y metodos para inhibir la expresion del gen de factor inducible por hipoxia alfa (hif2alfa). |
| ES2842300T3 (es) * | 2015-07-31 | 2021-07-13 | Alnylam Pharmaceuticals Inc | Composiciones de ARNi de transtiretina (TTR) y métodos para su uso para el tratamiento o la prevención de enfermedades asociadas con TTR |
| CN109069529B (zh) | 2016-03-07 | 2021-08-20 | 箭头药业股份有限公司 | 用于治疗性化合物的靶向配体 |
-
2015
- 2015-10-01 JO JOP/2021/0043A patent/JOP20210043A1/ar unknown
-
2016
- 2016-09-28 JO JOP/2016/0211A patent/JOP20160211B1/ar active
- 2016-09-30 US US15/281,309 patent/US9932586B2/en active Active
- 2016-09-30 SG SG10202008530TA patent/SG10202008530TA/en unknown
- 2016-09-30 PT PT168526952T patent/PT3356529T/pt unknown
- 2016-09-30 SI SI201631374T patent/SI3356529T1/sl unknown
- 2016-09-30 BR BR112018006489-0A patent/BR112018006489A2/pt active Search and Examination
- 2016-09-30 ES ES16852695T patent/ES2896298T3/es active Active
- 2016-09-30 IL IL300438A patent/IL300438A/en unknown
- 2016-09-30 HR HRP20211410TT patent/HRP20211410T1/hr unknown
- 2016-09-30 CR CR20180231A patent/CR20180231A/es unknown
- 2016-09-30 EP EP21191363.7A patent/EP4029941A1/en active Pending
- 2016-09-30 TW TW113106862A patent/TWI880645B/zh active
- 2016-09-30 HU HUE16852695A patent/HUE055942T2/hu unknown
- 2016-09-30 CN CN201680057095.8A patent/CN108368506A/zh active Pending
- 2016-09-30 EP EP16852695.2A patent/EP3356529B1/en active Active
- 2016-09-30 UY UY0001036926A patent/UY36926A/es active IP Right Grant
- 2016-09-30 TN TNP/2018/000094A patent/TN2018000094A1/en unknown
- 2016-09-30 WO PCT/US2016/054729 patent/WO2017059223A2/en not_active Ceased
- 2016-09-30 MY MYPI2018000440A patent/MY195796A/en unknown
- 2016-09-30 PE PE2018000487A patent/PE20181139A1/es unknown
- 2016-09-30 MX MX2018003833A patent/MX2018003833A/es unknown
- 2016-09-30 CA CA3000397A patent/CA3000397A1/en active Pending
- 2016-09-30 KR KR1020247036942A patent/KR20240162596A/ko active Pending
- 2016-09-30 AU AU2016331084A patent/AU2016331084B2/en active Active
- 2016-09-30 KR KR1020187010095A patent/KR102728481B1/ko active Active
- 2016-09-30 JP JP2018516738A patent/JP6991966B2/ja active Active
- 2016-09-30 EA EA201890864A patent/EA038478B1/ru unknown
- 2016-09-30 SM SM20210622T patent/SMT202100622T1/it unknown
- 2016-09-30 RS RS20211351A patent/RS62523B1/sr unknown
- 2016-09-30 PL PL16852695T patent/PL3356529T3/pl unknown
- 2016-09-30 LT LTEPPCT/US2016/054729T patent/LT3356529T/lt unknown
- 2016-09-30 TW TW105131823A patent/TWI784934B/zh active
- 2016-09-30 TW TW111141660A patent/TWI836693B/zh active
- 2016-09-30 DK DK16852695.2T patent/DK3356529T3/da active
- 2016-09-30 UA UAA201804593A patent/UA121998C2/uk unknown
-
2017
- 2017-04-06 MA MA43347A patent/MA43347B1/fr unknown
-
2018
- 2018-02-21 US US15/901,810 patent/US10662427B2/en active Active
- 2018-03-25 IL IL258333A patent/IL258333B/en unknown
- 2018-03-27 MX MX2022013010A patent/MX2022013010A/es unknown
- 2018-03-28 CL CL2018000803A patent/CL2018000803A1/es unknown
- 2018-03-28 PH PH12018500713A patent/PH12018500713A1/en unknown
- 2018-04-05 CO CONC2018/0003678A patent/CO2018003678A2/es unknown
-
2020
- 2020-05-06 US US16/867,925 patent/US20200263179A1/en not_active Abandoned
-
2021
- 2021-03-12 JP JP2021039949A patent/JP7116212B2/ja active Active
- 2021-08-30 ZA ZA2021/06265A patent/ZA202106265B/en unknown
- 2021-11-08 CY CY20211100962T patent/CY1125263T1/el unknown
-
2022
- 2022-02-13 IL IL290566A patent/IL290566B2/en unknown
- 2022-06-15 JP JP2022096415A patent/JP7442574B2/ja active Active
- 2022-12-05 AU AU2022283623A patent/AU2022283623B2/en active Active
-
2023
- 2023-11-27 JP JP2023199857A patent/JP2024009262A/ja not_active Withdrawn
-
2024
- 2024-06-17 US US18/745,289 patent/US20250115907A1/en active Pending
-
2025
- 2025-10-03 AU AU2025242219A patent/AU2025242219A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018003678A2 (es) | Composiciones y métodos para inhibir la expresión génica de lpa | |
| DOP2019000005A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
| ECSP20017905A (es) | AGENTES DE iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DE LA APOLIPOPROTEÍNA C-III (APOC3) | |
| MX2020001912A (es) | Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso. | |
| MX2021009673A (es) | Moduladores de ror-gamma. | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| GT201700167A (es) | Terapias de combinación para el tratamiento de cánceres. | |
| UY37098A (es) | Moduladores de ror-gamma | |
| MX2018001723A (es) | Conjugados farmaco-multiligando y usos de los mismos. | |
| DOP2012000257A (es) | Derivados del acido 1-amino-2-ciclopropiletilboronico | |
| MX2014015185A (es) | Derivados deuterados de ruxolitinib. | |
| MX2019014800A (es) | Agentes de iarn para la inhibicion de la expresion de alfa-enac y metodos de uso. | |
| EA201792103A1 (ru) | Композиции и способы для ингибирования экспрессии генов hif2альфа | |
| CO2018002198A2 (es) | Composiciones farmacéuticas que comprenden un compuesto oligomérico para modular la expresión de apolipoproteína (a) | |
| AR106227A1 (es) | COMPOSICIONES Y MÉTODOS PARA INHIBIR LA EXPRESIÓN GÉNICA DEL GEN DE LA APOLIPOPROTEÍNA APO(a) (LPA) | |
| DOP2014000221A (es) | Métodos para tratar el cáncer usando inhibidor de pi3k e inhibidor de mek | |
| AR112754A1 (es) | AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE a-ENaC Y MÉTODOS DE USO | |
| AR113014A1 (es) | AGENTES DE iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DE LA APOLIPOPROTEÍNA C-III (APOC3) | |
| AR105611A1 (es) | TERAPIA ARNi PARA INFECCIÓN POR VIRUS DE HEPATITIS B | |
| AR090580A1 (es) | Composiciones farmaceuticas para terapia combinada | |
| AR096390A1 (es) | COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO | |
| CU20120052A7 (es) | Derivados de pirazol que modulan estearoil-coa-desaturasa |